Understanding where a transgene integrates matters because the genomic position decides how it behaves: whether it expresses at the level you need, stays stable over time, or is gradually silenced. These position effects shape both the safety and efficacy of a cell or gene therapy and the titer and stability of a biomanufacturing line.
Annogen’s Integration Mapping (AIM™) measures those effects directly. We barcode and track more than 100,000 genomic loci in parallel, reading the expression each one supports, so the sites you choose rest on measured evidence rather than a short list of assumed-safe locations.
We start by defining what the design or integration site needs to support: expression strength, stability, cell-state response and the level of control required for the therapy.
AIM™ integrates a barcoded reporter or therapeutic construct across more than 100,000 genomic loci, making each integration site individually traceable.
Barcode-linked NGS/RNA readouts show how genomic position influences expression behavior, including strength, stability, variability and condition-specific response.
The result is a ranked view of candidate integration sites, based on how well they support the intended therapeutic expression profile.
AIM projects can be completed within as little as 3 months.
Find the genomic sites where your transgene expresses durably.
When your therapy allows targeted integration, the genomic locus becomes part of the design, not an afterthought. The handful of known safe-harbor sites are convenient, but they were never selected for your construct, your cell type or the expression behavior you need.
AIM™ widens that decision space. We integrate a barcoded version of your construct across >100,000 genomic positions in parallel and measure the expression each one drives, so you see which genomic environments give stable, controlled expression, and which silence it or push it too high.
The result is integration-site selection based on measured evidence rather than assumption. A study can be designed to elucidate novel, patentable loci, instead of relying on the same public safe harbors as everyone else.
Engineer promoters and enhancers when regulatory sequence design drives therapeutic expression control.
We imagine there could be some questions you want to ask us. Discover the most frequently asked questions about this subject right here.
Let’s start with your goals.
Share your challenge, question or ambitions. We will help you explore how our off-the-shelf promoters can support the decisions ahead.
